ProfileGDS5678 / 1443118_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 59% 61% 59% 60% 64% 68% 60% 61% 60% 61% 60% 62% 61% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7293562
GSM967853U87-EV human glioblastoma xenograft - Control 23.5532859
GSM967854U87-EV human glioblastoma xenograft - Control 33.6485961
GSM967855U87-EV human glioblastoma xenograft - Control 43.5222459
GSM967856U87-EV human glioblastoma xenograft - Control 53.5640160
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8737864
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.1710968
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6147160
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6292661
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6020160
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6310361
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5377560
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7052462
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6368961